. 2022 Feb 2;11(5):1292–1298. doi: 10.1002/cam4.4478

TABLE 2.

Summary of overall response rate

	Isatuximab 20 mg/kg (N = 14)
Complete response (CR), n	0
Complete response with incomplete peripheral recovery (CRi), ¹⁶ n	0
Relapsed disease, n	0
Progressive disease, n (%)	12 (87.5%) ^a
Responders, CR or CRi, n (95% CI)	0 (0.0%–23.2%)

^{^a}

11 patients had progressive disease as best response (one patient, who withdrew from the study because of suspected progressive disease, had his post‐treatment cancer therapy started 1 day before the confirmation of disease progression).